IL145044A0 - Vaccine - Google Patents

Vaccine

Info

Publication number
IL145044A0
IL145044A0 IL14504400A IL14504400A IL145044A0 IL 145044 A0 IL145044 A0 IL 145044A0 IL 14504400 A IL14504400 A IL 14504400A IL 14504400 A IL14504400 A IL 14504400A IL 145044 A0 IL145044 A0 IL 145044A0
Authority
IL
Israel
Prior art keywords
vaccine
Prior art date
Application number
IL14504400A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of IL145044A0 publication Critical patent/IL145044A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14504400A 1999-03-19 2000-03-17 Vaccine IL145044A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002467 WO2000056359A2 (en) 1999-03-19 2000-03-17 Vaccine against streptococcus pneumoniae

Publications (1)

Publication Number Publication Date
IL145044A0 true IL145044A0 (en) 2002-06-30

Family

ID=27451884

Family Applications (5)

Application Number Title Priority Date Filing Date
IL14504400A IL145044A0 (en) 1999-03-19 2000-03-17 Vaccine
IL14504300A IL145043A0 (en) 1999-03-19 2000-03-17 Vaccine
IL14504500A IL145045A0 (en) 1999-03-19 2000-03-17 Vaccine
IL145043A IL145043A (en) 1999-03-19 2001-08-22 Immunogenic compound and vaccines containing polysaccharide antigens
IL145044A IL145044A (en) 1999-03-19 2001-08-22 Immunogenic preparation and vaccines containing antigens linked to polysaccharides

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL14504300A IL145043A0 (en) 1999-03-19 2000-03-17 Vaccine
IL14504500A IL145045A0 (en) 1999-03-19 2000-03-17 Vaccine
IL145043A IL145043A (en) 1999-03-19 2001-08-22 Immunogenic compound and vaccines containing polysaccharide antigens
IL145044A IL145044A (en) 1999-03-19 2001-08-22 Immunogenic preparation and vaccines containing antigens linked to polysaccharides

Country Status (32)

Country Link
US (8) US20030147922A1 (enExample)
EP (6) EP1162999B1 (enExample)
JP (4) JP2002540074A (enExample)
KR (3) KR100798212B1 (enExample)
CN (3) CN100339130C (enExample)
AR (3) AR022964A1 (enExample)
AT (3) ATE387214T1 (enExample)
AU (3) AU750913B2 (enExample)
BE (1) BE1025464I2 (enExample)
BR (4) BR0009166A (enExample)
CA (3) CA2366314C (enExample)
CY (3) CY1107561T1 (enExample)
CZ (3) CZ303653B6 (enExample)
DE (4) DE60032120T2 (enExample)
DK (2) DK1162999T3 (enExample)
ES (3) ES2339737T3 (enExample)
FR (1) FR10C0008I2 (enExample)
HK (3) HK1043731B (enExample)
HU (4) HU229968B1 (enExample)
IL (5) IL145044A0 (enExample)
LU (1) LU91652I2 (enExample)
MX (1) MXPA01009452A (enExample)
MY (2) MY125202A (enExample)
NL (1) NL300415I1 (enExample)
NO (4) NO330736B1 (enExample)
NZ (3) NZ513841A (enExample)
PL (3) PL203917B1 (enExample)
PT (2) PT1162999E (enExample)
SI (2) SI1162999T1 (enExample)
TR (3) TR200102739T2 (enExample)
TW (3) TWI235064B (enExample)
WO (3) WO2000056358A2 (enExample)

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ATE335510T1 (de) 1998-05-22 2006-09-15 Ottawa Health Research Inst Methoden und produkte zur induzierung mukosaler immunität
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
WO2002034771A2 (en) 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
JP2005504718A (ja) 2001-01-23 2005-02-17 アヴェンティス パストゥール 多価髄膜炎菌多糖−タンパク質複合ワクチン
CA2438942A1 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP1531796B1 (en) 2002-02-20 2016-09-28 GlaxoSmithKline Biologicals SA Microparticles with adsorbed polypeptide-containing molecules
WO2003094960A2 (en) * 2002-05-14 2003-11-20 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
US7485710B2 (en) * 2002-10-15 2009-02-03 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
HUE034801T2 (en) 2002-11-01 2018-02-28 Glaxosmithkline Biologicals Sa Drying procedure
US10919956B2 (en) 2002-11-12 2021-02-16 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
PT2172213E (pt) * 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
CA2517439C (en) * 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
DE602004010376T2 (de) * 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
JP5718545B2 (ja) 2004-04-30 2015-05-13 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 髄膜炎菌結合体ワクチン接種
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
DK2682126T3 (en) 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
ES2595363T3 (es) 2005-02-18 2016-12-29 J. Craig Venter Institute, Inc. Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CN104815327A (zh) * 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
CA2605179A1 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics, Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
PL2878307T3 (pl) 2005-06-27 2020-01-31 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
CN101287488B (zh) 2005-09-01 2013-01-30 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PL3017827T3 (pl) 2005-12-22 2019-04-30 Glaxosmithkline Biologicals Sa Szczepionka z koniugatem polisacharydu pneumokokowego
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
NO346497B1 (no) * 2006-01-17 2022-09-05 Arne Forsgren Overflateeksponert haemophilus influenzae protein (protein E, pE)
CN101024079B (zh) * 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
KR101711903B1 (ko) * 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
CA2646993C (en) 2006-03-22 2016-01-26 Novartis Ag Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
KR101541383B1 (ko) * 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
PE20080774A1 (es) * 2006-03-30 2008-08-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende pnag de estafilococos conjugada con una proteina portadora y polisacarido u oligosacarido capsular de s. aureus
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
WO2008020335A2 (en) * 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
PT2074221E (pt) * 2006-10-10 2010-09-06 Wyeth Llc Métodos melhorados para a separação de polissacáridos tipo 3 de streptococcus pneumoniae
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US9610339B2 (en) * 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
NZ584683A (en) 2007-10-19 2012-05-25 Novartis Ag Neisseria meningitidis serogroup B vaccine formulations
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
WO2009094730A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
KR101573648B1 (ko) 2008-07-21 2015-12-01 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
AU2009309416B2 (en) 2008-10-27 2015-05-28 Glaxosmithkline Biologicals S.A. Purification method
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
BRPI0923006A2 (pt) 2008-12-17 2016-03-08 Novartis Ag vacinas meningococicas incluindo receptor de hemoglobina
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
ES2797504T3 (es) 2009-03-24 2020-12-02 Glaxosmithkline Biologicals Sa Proteína de enlace del factor H meningocócico utilizada como adyuvante
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
CA2758490C (en) 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
MX2012001194A (es) 2009-07-30 2012-03-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos.
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
ES2670576T3 (es) * 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
EP2493499A1 (en) 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
SMT201700275T1 (it) 2009-10-30 2017-07-18 Glaxosmithkline Biologicals Sa Purificazione di saccaridi capsulari di staphylococcus aureus tipo 5 e tipo 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
KR101635795B1 (ko) 2009-12-17 2016-07-04 피나 바이오솔루션스, 엘엘씨 다당류/단백질 접합체 백신의 제조에 있어서 시안화제인 1-시아노벤조트리아졸 (1-cbt)을 통한 다당류의 활성화
WO2011077309A2 (en) 2009-12-22 2011-06-30 Pfizer Vaccines Llc Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127302A2 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
CA2800174A1 (en) * 2010-05-20 2011-11-24 June L. Round Antigen specific tregs and related compositions, methods and systems
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
ES2614807T3 (es) * 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
KR101711250B1 (ko) 2011-05-06 2017-03-02 페트르 젠나디에비치 아파린 시겔라 소네이 박테리아의 세포외 다당류, 이를 제조하는 방법, 이를 함유한 백신 및 약제 조성물
JP6499446B2 (ja) 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
SG11201402375VA (en) 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
US20150273042A1 (en) 2012-02-24 2015-10-01 Novartis Ag Pilus proteins and compositions
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
RU2727476C2 (ru) 2012-04-26 2020-07-21 Новартис Аг Антигены и антигенные композиции
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
AU2013265336A1 (en) 2012-05-22 2014-12-04 Novartis Ag Meningococcus serogroup X conjugate
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
SG11201500978TA (en) 2012-10-03 2015-07-30 Glaxosmithkline Biolog Sa Immunogenic compositions
EP2906239A1 (en) 2012-10-12 2015-08-19 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
CN104853768B (zh) * 2012-10-17 2019-04-19 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
AU2014385320B2 (en) 2013-05-15 2019-10-10 The Governors Of The University Of Alberta E1E2 HCV vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北京科兴生物制品有限公司 一种含肠道病毒抗原的多价免疫原性组合物
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112016015835B1 (pt) * 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
KR20220080201A (ko) 2014-01-21 2022-06-14 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北京天成新脉生物技术有限公司 脑膜炎球菌荚膜多糖单克隆抗体及其应用
KR102761870B1 (ko) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
DK3244917T5 (da) 2015-01-15 2024-10-14 Pfizer Immunogene sammensætninger til anvendelse i pneumokokvacciner
CN104548090B (zh) * 2015-01-27 2016-11-30 中国科学院过程工程研究所 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
KR102800419B1 (ko) 2015-07-21 2025-04-25 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
EP4480544A3 (en) 2015-08-25 2025-03-26 Babita Agrawal Immunomodulatory compositions andmethods of use thereof
US11186615B2 (en) 2015-10-08 2021-11-30 The Governors Of The University Of Alberta Hepatitis C virus E1/E2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
TN2018000187A1 (en) 2015-12-04 2019-10-04 Dana Farber Cancer Inst Inc Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
SG11201805621SA (en) 2016-01-19 2018-08-30 Pfizer Cancer vaccines
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
KR102437120B1 (ko) 2016-08-05 2022-08-25 사노피 파스퇴르 인코포레이티드 다가 폐렴구균 다당류-단백질 접합체 조성물
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
WO2018104889A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Biologicals Sa Purification process for capsular polysaccharide
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110520154B (zh) * 2017-03-15 2023-08-04 株式会社Lg化学 多价肺炎链球菌疫苗组合物
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
CN110662557A (zh) 2017-03-31 2020-01-07 葛兰素史克知识产权开发有限公司 免疫原性组合物、用途和治疗方法
CN111132691A (zh) 2017-06-10 2020-05-08 创赏有限公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP2020530478A (ja) 2017-08-14 2020-10-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫応答を強化する方法
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
MX2020005779A (es) 2017-12-06 2020-10-28 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
BR112020014978A2 (pt) 2018-02-05 2020-12-22 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
CA3089007A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
HRP20230007T1 (hr) 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
TW202011985A (zh) 2018-04-18 2020-04-01 韓商Ｓｋ生物科學股份有限公司 肺炎鏈球菌的莢膜多醣類以及其免疫原性接合體
CA3106291A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020120569A2 (en) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
US12404533B2 (en) 2019-01-11 2025-09-02 Northwestern University Bioconjugate vaccines' synthesis in prokaryotic cell lysates
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
CA3129425A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020212461A1 (en) 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
BR112021022429A2 (pt) 2019-05-10 2022-03-22 Glaxosmithkline Biologicals Sa Produção de conjugados
AU2020325569B2 (en) 2019-08-05 2024-01-18 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein D polypeptide
US20230066762A1 (en) 2019-08-05 2023-03-02 Glaxosmithkline Biologicals Sa Immunogenic composition
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20230105457A1 (en) 2019-10-16 2023-04-06 Enterome S.A. Immunogenic Compounds For Treatment Of Adrenal Cancer
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
EP4021487B1 (en) 2019-11-15 2023-12-27 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy
JP2023503086A (ja) 2019-11-22 2023-01-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細菌サッカリド複合糖質ワクチンの用法及び用量
US20220409539A1 (en) * 2019-12-30 2022-12-29 Fraunhofer Usa Inc. Particles for multi-dose delivery
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
CN111588847B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种含有单磷酸化的脂质a与糖抗原的缀合物及其制备方法和应用
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
EP4192499A4 (en) 2020-08-10 2024-09-25 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
TW202227467A (zh) 2020-10-27 2022-07-16 美商輝瑞大藥廠 大腸桿菌組合物及其方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4240410A1 (en) 2020-11-04 2023-09-13 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
JP7714690B2 (ja) 2021-05-28 2025-07-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
MX2024008039A (es) 2022-01-13 2024-07-10 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos.
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
EP4522208A1 (en) 2022-05-11 2025-03-19 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
IL321062A (en) 2022-11-22 2025-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121057590A (zh) 2023-04-14 2025-12-02 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
CN120404993B (zh) * 2025-07-03 2025-10-03 成都迈科康生物科技有限公司 一种检测样本中mpl的方法及其相关应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HUT58804A (en) * 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
WO1994006465A1 (en) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Antigen of hybrid m protein and carrier for group a streptococcal vaccine
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
WO1994026304A1 (en) 1993-05-18 1994-11-24 Ohio State Research Foundation Otitis media vaccine
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
AU716806B2 (en) * 1995-04-17 2000-03-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
WO1996040242A1 (en) 1995-06-07 1996-12-19 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
WO1996040928A1 (en) 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
ATE323721T1 (de) 1996-05-01 2006-05-15 Univ Rockefeller Cholin-bindendes protein, welches als gegen pneumokokken gerichtetes vakzin verwendet wird
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk グレーチング
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
JP2001502925A (ja) 1997-06-03 2001-03-06 コノート ラボラトリーズ リミテッド モラクセラのラクトフェリン受容体遺伝子
JP2001510031A (ja) 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
ES2343492T3 (es) 1998-04-07 2010-08-02 Medimmune, Llc Derivados de proteinas neumococicas de union a colina para vacunas.
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
CA2340692A1 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
DK1140157T3 (da) * 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner
EP1162999B1 (en) * 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 富士康(昆山)电脑接插件有限公司 线缆连接器组件

Also Published As

Publication number Publication date
ATE346608T1 (de) 2006-12-15
CY2009014I2 (el) 2010-07-28
NO20014325L (no) 2001-11-14
BE1025464I2 (enExample) 2019-03-06
JP2002540074A (ja) 2002-11-26
ES2339737T3 (es) 2010-05-25
SI1163000T1 (sl) 2008-06-30
PL355178A1 (en) 2004-04-05
DK1162999T3 (da) 2007-03-26
AU3430700A (en) 2000-10-09
CA2366314A1 (en) 2000-09-28
EP1163000B1 (en) 2008-02-27
AU750913B2 (en) 2002-08-01
TWI286938B (en) 2007-09-21
EP1162998A2 (en) 2001-12-19
US20100119544A1 (en) 2010-05-13
PL203917B1 (pl) 2009-11-30
IL145045A0 (en) 2002-06-30
US20060002961A1 (en) 2006-01-05
BR0009154A (pt) 2001-12-26
HU229968B1 (hu) 2015-03-30
HK1043730A1 (zh) 2002-09-27
WO2000056358A3 (en) 2001-01-04
NO20014322L (no) 2001-11-14
EP2277535A3 (en) 2011-03-09
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
DE60032120T2 (de) 2007-09-20
TR200102735T2 (tr) 2002-04-22
CN1351503A (zh) 2002-05-29
AR022963A1 (es) 2002-09-04
LU91652I2 (fr) 2010-10-13
FR10C0008I2 (fr) 2012-10-26
PL204890B1 (pl) 2010-02-26
MY125387A (en) 2006-07-31
CA2366314C (en) 2012-01-10
DE60032120D1 (de) 2007-01-11
US20030147922A1 (en) 2003-08-07
WO2000056360A2 (en) 2000-09-28
WO2000056359A2 (en) 2000-09-28
US20050031646A1 (en) 2005-02-10
IL145043A0 (en) 2002-06-30
US20110217329A1 (en) 2011-09-08
ATE459373T1 (de) 2010-03-15
NO2011014I1 (no) 2011-09-19
MY125202A (en) 2006-07-31
ES2300255T3 (es) 2008-06-16
EP2277535A2 (en) 2011-01-26
HUP0200373A2 (en) 2002-06-29
BRPI0009163B8 (pt) 2021-05-25
NL300415I1 (nl) 2009-12-01
CY1107561T1 (el) 2013-03-13
EP1162999B1 (en) 2006-11-29
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
DE60038166D1 (de) 2008-04-10
TR200102739T2 (tr) 2001-12-21
MXPA01009452A (es) 2002-08-06
BR0009166A (pt) 2001-12-26
NO20014325D0 (no) 2001-09-05
AR022965A1 (es) 2002-09-04
DK1163000T3 (da) 2008-04-28
PT1162999E (pt) 2007-02-28
JP2002539273A (ja) 2002-11-19
HU228499B1 (en) 2013-03-28
HK1043728B (en) 2007-06-22
TWI235064B (en) 2005-07-01
ES2275499T3 (es) 2007-06-16
WO2000056358A2 (en) 2000-09-28
CY1107390T1 (el) 2010-07-28
AU750762B2 (en) 2002-07-25
NO330736B1 (no) 2011-06-27
KR100642044B1 (ko) 2006-11-10
KR20020001785A (ko) 2002-01-09
US9168313B2 (en) 2015-10-27
TWI281403B (en) 2007-05-21
EP1163000A2 (en) 2001-12-19
CZ20013380A3 (cs) 2002-03-13
AR022964A1 (es) 2002-09-04
WO2000056360A3 (en) 2001-01-25
BR0009163A (pt) 2001-12-26
EP1776962A1 (en) 2007-04-25
EP1880735A3 (en) 2008-03-12
CN1192798C (zh) 2005-03-16
EP1880735A2 (en) 2008-01-23
IL145044A (en) 2007-03-08
JP4846906B2 (ja) 2011-12-28
AU3291900A (en) 2000-10-09
NZ513842A (en) 2004-05-28
BRPI0009163B1 (pt) 2019-04-09
TR200102736T2 (tr) 2002-04-22
CZ20013378A3 (cs) 2002-03-13
US8926985B2 (en) 2015-01-06
SI1162999T1 (sl) 2007-04-30
DE60038166T2 (de) 2009-03-12
AU750788B2 (en) 2002-07-25
CN1191852C (zh) 2005-03-09
CZ303653B6 (cs) 2013-01-30
CY2009014I1 (el) 2010-07-28
NO330532B1 (no) 2011-05-09
KR20020000785A (ko) 2002-01-05
PL355264A1 (en) 2004-04-05
NO2011014I2 (no) 2011-08-30
CN1351501A (zh) 2002-05-29
HUP0200664A2 (en) 2002-06-29
DE122009000054I1 (de) 2009-12-31
NL300415I2 (enExample) 2016-12-13
HK1043728A1 (en) 2002-09-27
FR10C0008I1 (fr) 2010-03-26
IL145043A (en) 2007-06-17
NZ513841A (en) 2001-09-28
LU91652I9 (enExample) 2019-01-03
KR20020000549A (ko) 2002-01-05
CA2365296A1 (en) 2000-09-28
NO20014323D0 (no) 2001-09-05
AU3813600A (en) 2000-10-09
NZ513840A (en) 2004-02-27
DE60043930D1 (de) 2010-04-15
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
JP5551579B2 (ja) 2014-07-16
HUP0200367A2 (en) 2002-05-29
CN1391481A (zh) 2003-01-15
EP1162998B1 (en) 2010-03-03
CZ301445B6 (cs) 2010-03-03
EP1162999A2 (en) 2001-12-19
CZ20013379A3 (cs) 2002-03-13
NO20014322D0 (no) 2001-09-05
KR100798212B1 (ko) 2008-01-24
JP2002540075A (ja) 2002-11-26
JP2011057713A (ja) 2011-03-24
HUS1500040I1 (hu) 2018-05-28
WO2000056359A3 (en) 2001-02-01
PL355180A1 (en) 2004-04-05
HK1043731B (en) 2009-01-23
US20060093626A1 (en) 2006-05-04
HK1043731A1 (en) 2002-09-27
ATE387214T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
IL145045A0 (en) Vaccine
HUS1300072I1 (hu) Vakcina
HUP0202885A3 (en) Vaccines
HUP0203056A3 (en) Vaccine composition
GB9910812D0 (en) Vaccine composition
GB9901254D0 (en) Vaccines
GB9915204D0 (en) Vaccine
GB0027072D0 (en) Vaccine
GB9906437D0 (en) Vaccine
GB9913327D0 (en) Vaccine
MXPA01010701A (es) Vacuna.
GB9930591D0 (en) Component for vaccine
GB9909072D0 (en) Vaccine
GB9922700D0 (en) Vaccine
GB9930585D0 (en) Component for vaccine
GB9915205D0 (en) Vaccine
GB9904412D0 (en) Vaccine
GB9925619D0 (en) Vaccine
GB9925618D0 (en) Vaccine
GB9922703D0 (en) Vaccine
GB9916677D0 (en) Vaccine
GB9922701D0 (en) Vaccine
GB9919260D0 (en) Vaccine
GB9904405D0 (en) Vaccine
GB9904408D0 (en) Vaccine

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed